Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 103-111

  Karl, Theresia ^a   Seibert, Nadine ^a   Stöhr, Michael ^b   Osswald, Hans ^c   Rösl, Frank ^a   Finzer, Patrick ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Forschungsschwerpunkt Zytometrie   (Germany)

^c Forschungsschwerpunkt Krebsrisikofaktoren und Prävention   (Germany)

Author keywords

Apoptosis; Growth arrest; HPV E7 degradation

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACTIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN 1; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROTEASOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN E7; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; SULINDAC; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; UTERINE CERVIX CARCINOMA; VIRUS TRANSCRIPTION; WART VIRUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CYCLINS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; CYSTEINE PROTEINASE INHIBITORS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HUMANS; LEUPEPTINS; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; S PHASE; SULFONAMIDES; SULINDAC; THIAZINES; THIAZOLES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 33845627233     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.034     Document Type: Article

References (57)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350
2. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., and Gissmann L. Correlation of modified human papillomavirus early gene exprssion with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res. 48 (1988) 3780-3786
3. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
4. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
5. O'Byrne K.J., and Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 85 (2001) 473-483
6. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
7. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
8. Gupta R.A., and DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1 (2001) 11-21
9. Gaffney D.K., Golden J., Zempolich K., Murphy K.J., Dicker A.P., and Dodson M. Elevated COX-2 expression in cervical carcinoma. Am. J. Clin. Oncol. 24 (2001) 443-446
10. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 (2001) 429-434
11. Sun Y., Tang X.M., Half E., Kuo M.T., and Sinicrope F.A. Cylooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 62 (2002) 6323-6328
12. Liu C.H., Chang S., Narko K., Trifan O.C., Wu M., Smith E., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276 (2001) 18563-18569
13. Frolich J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 18 (1997) 30-34
14. Masferrer J.L., Koki A., and Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. NY Acad. Sci. 889 (1999) 84-86
15. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94 (2001) 252-266
16. Winde G., Schmid K.W., Brandt B., Muller O., and Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis. Colon Rectum 40 (1997) 1156-1168
17. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.D., and Phillips K.R. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80 (1993) 1618-1619
18. Pasricha P.J., Bedi A., O'Connor K., Rashid A., Akhtar A.J., Zahurak L.M., et al. The effect of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109 (1995) 994-998
19. Dickinson R.G., and King A.R. Studies on the reactivity of acyl glucuronides-V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase. Biochem. Pharmacol. 46 (1993) 1175-1182
20. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol/chloroform extraction. Anal. Biochem. 162 (1987) 156-159
21. Khandjian E.W., and Meric C. A procedure for northern blot analysis of native RNA. Anal. Biochem. 159 (1986) 227-232
22. Feinberg A., and Vogelstein B.A. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 137 (1984) 266-267
23. Gunning P., Ponte P., Okayama H., Blau H., and Kedes L. Isolation and characterization of full-length cDNA clones for human α-, β-, and γ-actin mRNA: skeletal but not cytoplasmic actins have an amino-terminal cystein that subsequently removed. Mol. Cell. Biol. 3 (1983) 787-795
24. Gardiol D., Kühne C., Glaunsinger B., Lee S.S., Javier R., and Banks L. Oncogenic human papillomavirus E6 proteins target the disc large tumour suppressor for proteasome-mediated degradation. Oncogene 18 (1999) 5487-5496
25. Chen C., and Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 8 (1987) 2745-2752
26. Stoehr M., Vogt-Schaden M., Knobloch M., Vogel R., and Futterman G. Evaluation of eight fluorochrome combinations for simultaneous DNA-protein flow analysis. Stain Technol. 55 (1978) 205-215
27. Dean P.N., and Jett J.H. Mathematical analysis of DNA distributions derived from flow microfluorometry. J. Cell Biol. 60 (1974) 523
28. Finzer P., Soto U., Delius H., Patzelt A., Coy J.F., Poustka A., et al. Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV18 positive cells: the role of the chromatin structure and AP-1 composition. Oncogene 19 (2000) 3235-3244
29. Blomberg I., and Hoffmann I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell. Biol. 19 (1999) 6183-6194
30. Swanton C. Cell-cycle targeted therapies. Lancet Oncol. 5 (2004) 27-36
31. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1 (2001) 222-231
32. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
33. Ekhom S.V., and Reed S.I. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12 (2000) 676-684
34. Finzer P., Kuntzen C., Soto U., zur Hausen H., and Rösl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20 (2001) 4768-4776
35. He W., Staples D., Smith C., and Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 77 (2003) 10566-10574
36. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem. Pharmacol. 63 (2002) 343-347
37. Blanco F.J., Guitian R., Moreno J., de Toro F.J., and Galdo F. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J. Rheumatol. 26 (1999) 1366-1373
38. Reinstein E., Scheffner M., Oren M., Ciechanover A., and Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19 (2000) 5944-5950
39. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2 (2002) 277-288
40. Chen Y.J., Wang L.S., Wang P.H., Lai C.R., Yen M.S., Ng H.T., et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol. Oncol. 88 (2003) 379-385
41. Sales K.J., Katz A.A., Howard B., Soeters R.P., Millar R.P., Jabbour H.N., et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 62 (2002) 424-432
42. Anderson W.F., Ulmar A., Viner J.L., and Hawk E.T. The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. Des. 8 (2002) 1035-1062
43. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Fed. Am. Soc. Exp. Biol. J. 15 (2001) 2057-2072
44. Kroemer H.K., and Klotz U. Glucuronidation of drugs-a reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet. 23 (1992) 292-310
45. Reed R.G., Davidson L.K., Burrington C.M., and Peters Jr. T. Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin. Clin. Chem. 34 (1988) 1992-1994
46. Wang J., Sampath A., Raychaudhuri P., and Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20 (2001) 4740-4749
47. Oh K.-J., Kalinina A., Wang J., Nakayama K., Nakayama K.I., and Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and cullin 1- and skp2-containing E3 ligase. J. Virol. 78 (2004) 5338-5346
48. Kamio M., Yoshida T., Ogata H., Douchi T., Nagata Y., Inoue M., et al. SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. Oncogene 23 (2004) 3107-3115
49. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
50. Banks L., Barnett S.C., and Crook T. HPV-16 E7 functions at the G1 to S phase transition in the cell cycle. Oncogene 5 (1990) 833-837
51. Keller J.J., Offerhaus G.J., Polak M., Goodman S.N., Zahurak M.L., Hylind L.M., et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 45 (1999) 822-828
52. Piazza G.A., Rahm A.L., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55 (1995) 3110-3116
53. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57 (1997) 2452-2459
54. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
55. vander Heiden M.G., and Thompson C.B. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?. Nat. Cell Biol. 1 (1999) E209-E216
56. Nauenburg S., Zwerschke W., and Jansen-Dürr P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. Fed. Am. Soc. Exp. Biol. J. 15 (2001) 592-594
57. Stanley M. Chapter 17: genital human papillomavirus infections-current and prospective therapies. J. Natl Cancer Inst. Monogr. 31 (2003) 117-124